Urinary Triaosylceramide (GB3) as a Marker of Cardiac Disease
    4.
    发明申请
    Urinary Triaosylceramide (GB3) as a Marker of Cardiac Disease 审中-公开
    尿铁酸钠(GB3)作为心脏病标记物

    公开(公告)号:US20150342939A1

    公开(公告)日:2015-12-03

    申请号:US14729630

    申请日:2015-06-03

    Abstract: The present invention describes a method for determination of urinary globotriaosylceramide (Gb3) levels in non-Fabry disease cardiac patients. Determination of Gb3 levels provides a screening method for determining cardiac risk and may offer an alternative therapeutic option for cardiac disease management or cardiac disease risk mitigation by lowering Gb3 levels by the use of pharmacological chaperones or other agents.

    Abstract translation: 本发明描述了非法布里病心脏病患者尿球蛋白神经酰胺(Gb3)水平的测定方法。 Gb3水平的测定提供了一种用于确定心脏病风险的筛选方法,并且可以通过使用药理学伴侣或其他药物降低Gb3水平来提供心脏疾病管理或心脏疾病风险缓解的替代治疗选择。

Patent Agency Ranking